 phase II study combination carboplatin ifosfamide metastatic small cell lung carcinoma Phase II study combination active agents small cell lung carcinoma SCLC carboplatin ifosfamide Thirty patients men women median age years study Twelve patients metastatic site metastatic sites median performance status chemotherapy CT regimen course study carboplatin ifosfamide mesna weeks patients evaluable complete remission CR partial remission PR objective response rate median response time months median survival time months range months Bone marrow toxicity Grade III patients Grade IV patients carboplatin ifosfamide combination cross-resistance doxorubicin etoposide regimen patients combination cisplatin ifosfamide carboplatin regimen ifosfamide carboplatin combination inclusion non-cross-resistant CT schedules